The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.

Bisphosphonates are effective in the management of bone disease in patients with multiple myeloma and recent reports have suggested that they may also have an anti-tumour activity. In support of this, we have previously demonstrated that bisphosphonates can induce myeloma cell apoptosis in vitro; ho...

Podrobná bibliografie
Hlavní autoři:	Shipman, C, Vanderkerken, K, Rogers, M, Lippitt, J, Asosingh, K, Hughes, D, Van Camp, B, Russell, R, Croucher, P
Médium:	Journal article
Jazyk:	English
Vydáno:	2000

Podobné jednotky

Bisphosphonates--mechanisms of action in multiple myeloma.
Autor: Shipman, C, a další
Vydáno: (2000)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Autor: Croucher, P, a další
Vydáno: (2003)

Bisphosphonates and in vivo models of multiple myeloma - Reply
Autor: Shipman, C, a další
Vydáno: (2001)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
Autor: Vanderkerken, K, a další
Vydáno: (2003)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
Autor: Croucher, P, a další
Vydáno: (2001)

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.
Autor: Shipman, C, a další
Vydáno: (1997)

The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
Autor: Shipman, C, a další
Vydáno: (1998)

Anti-tumour activity of bisphosphonates in human myeloma cells.
Autor: Shipman, C, a další
Vydáno: (1998)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
Autor: Croucher, P, a další
Vydáno: (2000)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
Autor: Croucher, P, a další
Vydáno: (2001)

Osteoprotegerin and the development of myeloma bone disease
Autor: Croucher, P, a další
Vydáno: (2004)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
Autor: Croucher, P, a další
Vydáno: (2002)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
Autor: Croucher, P, a další
Vydáno: (2001)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
Autor: Croucher, P, a další
Vydáno: (2002)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
Autor: Shipman, C, a další
Vydáno: (2000)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
Autor: Shipman, C, a další
Vydáno: (2002)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
Autor: Mueller, G, a další
Vydáno: (2004)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
Autor: Mueller, G, a další
Vydáno: (2004)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
Autor: Shipman, C, a další
Vydáno: (2002)

Nitrogen-containing bisphosphonates induce apoptosis in human bone marrow-derived myeloma cells in vitro by inhibiting protein prenylation.
Autor: Gordon, S, a další
Vydáno: (1999)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
Autor: Edwards, C, a další
Vydáno: (2007)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
Autor: De Leenheer, E, a další
Vydáno: (2004)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
Autor: Shipman, C, a další
Vydáno: (2000)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
Autor: De Leenheer, E, a další
Vydáno: (2002)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
Autor: Locklin, R, a další
Vydáno: (2005)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
Autor: Croucher, P, a další
Vydáno: (2003)

The bisphosphonate-ester apornine does not act by inhibiting protein prenylation, but enhances the effects of lovastatin on myeloma cells
Autor: Roelofs, A, a další
Vydáno: (2006)

Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment
Autor: Richard Derman, a další
Vydáno: (2009-09-01)

Osteoblasts protect multiple myeloma cells from T-cell-induced apoptosis
Autor: Locklin, R, a další
Vydáno: (2007)

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
Autor: Liesbeth Bieghs, a další
Vydáno: (2010-01-01)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
Autor: Shipman, C, a další
Vydáno: (2002)

The Effectiveness of Zoledronic Acid and Ibandronic Acid in Delaying Skeletal-Related Events in Multiple Myeloma in Indonesia
Autor: Nutrisia Aquariushinta Sayuti, a další
Vydáno: (2020-09-01)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
Autor: Shipman, C, a další
Vydáno: (2003)

Administration of bisphosphonate (ibandronate) impedes molar tooth movement in rabbits: A radiographic assessment
Autor: V Venkataramana, a další
Vydáno: (2014-01-01)

Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
Autor: Clive Henry Buckle, a další
Vydáno: (2012-01-01)

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
Autor: Jagdev, S, a další
Vydáno: (2001)

NE10790, a phosphonocarboxylate analogue of risedronate, induces human myeloma cell apoptosis in vitro
Autor: Roelofs, A, a další
Vydáno: (2004)

Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment.
Autor: Locklin, R, a další
Vydáno: (2007)

P948: REAL-WORLD EVIDENCE OF BISPHOSPHONATES FOR MULTIPLE MYELOMA
Autor: Maria Nieves Lopez Muñoz, a další
Vydáno: (2023-08-01)

The pharmacology of bisphosphonates and new insights into their mechanisms of action.
Autor: Russell, R, a další
Vydáno: (1999)